Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D.
April 13, 2021
· 4 min read